FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEME
Section 16. Form 4 or Form 5	
obligations may continue See	

ENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Section 16 obligations Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

				0	r Section	on 30(h) d	of the	Investment C	Company Act	of 1940						
1. Name and Address of Reporting Person* Munsie Jeffrey A				$ \underline{\mathbf{N}} $	2. Issuer Name and Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC [MACK]						(Ch		cable) or (give title	g Perso	10% Own Other (sp	ner
(Last)	(F	First)	(Middle)		2 Date of Faulicat Transaction (Month/Day/Mass)						_	below)	below) General Couns			
C/O MERRIMACK PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/15/2018						General Counser					
ONE KENDALL SQUARE, SUITE B7201											6. Individual or Joint/Group Filing (Check Applicable					
(0)				— ^{4.}	If Ame	ndment, I	Date	of Original Fil	ed (Month/Da	ay/Year)	6. II		Joint/Group	Filing (Check App	licable
(Street) CAMBR	IDGE M	1A	02139									X Form f	iled by One	Report	ting Person	
Crivibi	indu iv		02155									Form f Persor	iled by More	e than (One Report	ing
(City)	(5	State)	(Zip)									. 0.00.				
		Tab	ole I - Non-D	erivativ	re Se	curities	s Ac	quired, D	isposed o	of, or Be	neficial	ly Owned	l			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)				Benefici	es ally Following	6. Own Form: I (D) or I (I) (Inst	Direct o Indirect E tr. 4) C	7. Nature of Indirect Beneficial Ownership
							Code V	Amount	(A) or (D)	Price	Transact (Instr. 3	tion(s)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Execut (Month/Day/Year) if any	3A. Deemed Execution Date if any (Month/Day/Yea	Code	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		y E	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$10.74	02/15/2018		A		45,000		(1)	02/14/2028	Common Stock	45,000	\$0.00	45,000		D	

Explanation of Responses:

1. This option vests as to 1/12th of the total number of shares granted on 5/15/18 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 2/15/21.

Remarks:

/s/ Brian J. Kickham, attorneyin-fact

02/16/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.